

Westminster Health Forum Keynote Seminar:

Next steps for cancer care: commissioning, integration, research and improving outcomes

Timing: Morning, Tuesday, 1st July 2014

Venue: The Caledonian Club, 9 Halkin Street, London SW1X 7DR

Draft agenda subject to change



WESTMINSTER
HEALTH FORUM

- 8.30 - 9.00 Registration and coffee
- 9.00 - 9.05 **Chairman's opening remarks**
Baroness Morgan of Drefelin, Chief Executive, Breast Cancer Campaign
- 9.05 - 9.25 **'Earlier Diagnosis - Cancer's Magic Key'**
John Baron MP, Chair, All-Party Parliamentary Group on Cancer
Questions and comments from the floor
- 9.25 - 9.35 **Opportunities for the independent sector**
Professor Karol Sikora, Chief Medical Officer, Cancer Partners UK
- 9.35 - 10.20 **Commissioning, integration, early diagnosis and reducing inequalities**
What impact will further integration of health and social care have on cancer services and outcomes, and what opportunities exist for commissioners to redesign services in areas such as rehabilitative care? In what further ways can professionals across primary care and public health work together to improve early diagnosis rates? Following cuts in funding and staffing from the old system of networks, how effectively are clinical senates and networks proving in informing commissioning decisions and in improving quality? What impact is cancer registration data having on improving outcomes in preventing premature mortality? How can the challenges of reducing inequalities in cancer services and outcomes - such as regional variations in the prevalence of public health issues - be overcome?
Dr Clare Stephens, Cancer Lead, NHS Barnet Clinical Commissioning Group
Dr Jem Rashbass, National Director for Disease Registration, Public Health England
Bernadette Lavery, Clinical Director for Cancer, Strategic Clinical Network (Thames Valley), NHS England
Owen Sharp, Chief Executive, Prostate Cancer UK
Questions and comments from the floor with **Professor Karol Sikora**, Chief Medical Officer, Cancer Partners UK
- 10.20 - 10.25 **Chairman's closing remarks**
Baroness Morgan of Drefelin, Chief Executive, Breast Cancer Campaign
- 10.25 - 10.50 Coffee
- 10.50 - 10.55 **Chairman's opening remarks**
James Clappison MP, Vice-Chair, All-Party Parliamentary Group on Cancer
- 10.55 - 11.15 **Next steps for improving cancer services**
Ciarán Devane, Chief Executive, Macmillan Cancer Support and Non-Executive Director, NHS England
Questions and comments from the floor
- 11.15 - 11.25 **'Accelerating progress through research'**
Sarah Woolnough, Executive Director of Policy and Information, Cancer Research UK
- 11.25 - 11.35 **Medicines and the Cancer Drugs Fund**
Professor Peter Clark, Chair, National Cancer Drugs Fund
- 11.35 - 11.45 **Stratified medicine and personalised treatment**
Professor Adrian Newland, Chair, Diagnostic Assessment Programme, NICE and Clinical Director for Pathology, Barts Health NHS Trust
- 11.45 - 12.00 Questions and comments from the floor
- 12.00 - 12.10 **'New frontiers in cancer treatment: immuno-oncology'**
Scott Cooke, Business Unit Director, Oncology, UK & Ireland, Bristol-Myers Squibb
- 12.10 - 12.55 **Access, value-based assessments, and patient involvement**
What opportunities exist for improving access to treatment and specialist health professionals, and what are the implications of new, targeted and stratified treatments for commissioners, providers and regulators? What should be the next steps for the delivery of Patient Reported Outcomes Measures (PROMs) and the cancer Recovery Package? Increased survivorship among cancer patients does bring new challenges for the NHS and social care more widely such as issues of resource allocation - how should these be addressed? Following the setting up of the Radiotherapy Innovation Fund, how can it be ensured that targets for patient access to advanced forms of radiotherapy are met? How effective are current models of health technology assessment in measuring the full value of cancer treatments - to producers, providers and patients? Should more be done to involve patients and clinicians in health technology assessments, and what more can be done to engage patients with their care pathways and to encourage further use of holistic needs assessments?
Eric Low, Chief Executive, Myeloma UK
Nick Hyde, Clinical Director, London Cancer Alliance
Dr Krishnaswamy Madhavan, Clinical Oncologist, Southend University Hospital NHS Foundation Trust
Questions and comments from the floor with **Scott Cooke**, Business Unit Director, Oncology, UK & Ireland, Bristol-Myers Squibb
- 12.55 - 13.00 **Chairman's and Westminster Health Forum closing remarks**
James Clappison MP, Vice-Chair, All-Party Parliamentary Group on Cancer
Steve Moat, Senior Producer, Westminster Health Forum

Seminar supported by **Bristol-Myers Squibb** and **Celgene**



Bristol-Myers Squibb



As Associate Sponsors